KR900701261A - 비만증 치료방법 - Google Patents

비만증 치료방법

Info

Publication number
KR900701261A
KR900701261A KR1019900701628A KR900701628A KR900701261A KR 900701261 A KR900701261 A KR 900701261A KR 1019900701628 A KR1019900701628 A KR 1019900701628A KR 900701628 A KR900701628 A KR 900701628A KR 900701261 A KR900701261 A KR 900701261A
Authority
KR
South Korea
Prior art keywords
obesity
cyclobutyl
chlorophenyl
dimethyl
treatment
Prior art date
Application number
KR1019900701628A
Other languages
English (en)
Other versions
KR0164435B1 (ko
Inventor
리 샤인바움 몬티
Original Assignee
아이. 에이. 하우틴
더 부츠 캄파니 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23060006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900701261(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아이. 에이. 하우틴, 더 부츠 캄파니 피엘씨 filed Critical 아이. 에이. 하우틴
Publication of KR900701261A publication Critical patent/KR900701261A/ko
Application granted granted Critical
Publication of KR0164435B1 publication Critical patent/KR0164435B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

비만증 치료방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 치료 유효량이 N, N-디메틸-1-[1- (4-클로로페닐) 사이클로부틸]-3-메틸부틸아민 이드로클로라이드를 약학적으로 허용되는 희석제 또는 담체와 함께 비만증 치료를 요하는 사람에 투여함을 특징으로 하여, 사필의 비만증을 치료하는 방법.
  2. 제1항에 있어서, N,N-디메틸-1-(1- (4-클로로페닐) 사이클로부틸)-3-메틸부틸아민 하이드로클로라이드가 이의 모노하이드레이트 형태로 투여되는 방법.
  3. 비만증 치료용 약제의 제조에 있어서, N,N-디메틸-1-[(4-클로로페닐)사이클로부틸]-3-메틸부틸아민 하이드로 클로라이드의 용도.
  4. 비만중 치료용 약제의 제조에 있어서, N,N-디메틸-1-[1- (4-클로로페닐)사이클로부틸)-3-메틸부틸아민 하이드로 클로라이드 모노하이드레이트의 용도.
  5. 비만증 치료에 있어서, N, N-디메틸 -1-[1- (4-클로로 페닐)사이클로부틸]-3-메틸부틸아민 하이드 로클로라이드의 용도.
  6. 비만증 치료에 있어서, N, N-디메틸-1-[1-(4-클로로 페닐) 사이클로부틸)-3-메틸부틸아민 하이 드로클로라이드 모노하이드레이트의 용도.
  7. 치료 유효량의 N, N-디메틸-1- [1- (4-클로로페닐) 사이클로부틸)-3-메틸부틸아민 하이드로클로라 이드를 약학적으로 허용되는 희석제 또는 담체와 함께 함유함을 특징으로 하는, 비만증 치료용 약학 조성물.
  8. 치료 유효량의 N,N-디메틸-1-[1-(4-클로로페닐) 사이클로부틸)-3-메틸부틸아민 하이드로클로라이드 모노 하이드레이트를 약학적으로 허용되는 희석제 또는 담체와 함께 함유함을 특징으로 하는, 비만증 치료용 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900701628A 1988-11-29 1989-11-21 비만증 치료용 약제학적 조성물 KR0164435B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27724088A 1988-11-29 1988-11-29
US07/277240 1988-11-29
US7/277240 1988-11-29
PCT/GB1989/001383 WO1990006110A1 (en) 1988-11-29 1989-11-21 Treatment of obesity

Publications (2)

Publication Number Publication Date
KR900701261A true KR900701261A (ko) 1990-12-01
KR0164435B1 KR0164435B1 (ko) 1999-01-15

Family

ID=23060006

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900701628A KR0164435B1 (ko) 1988-11-29 1989-11-21 비만증 치료용 약제학적 조성물

Country Status (16)

Country Link
US (1) US5436272A (ko)
EP (1) EP0397831B1 (ko)
JP (1) JPH06102622B2 (ko)
KR (1) KR0164435B1 (ko)
AU (1) AU633529B2 (ko)
CA (1) CA2003524C (ko)
DE (2) DE19975039I2 (ko)
DK (1) DK175587B1 (ko)
HK (1) HK1006002A1 (ko)
IE (1) IE61928B1 (ko)
IL (1) IL92406A (ko)
LU (1) LU90866I2 (ko)
NL (1) NL300066I2 (ko)
PH (1) PH26677A (ko)
WO (1) WO1990006110A1 (ko)
ZA (1) ZA899058B (ko)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
AU721924B2 (en) * 1992-06-23 2000-07-20 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
WO1994000114A1 (en) * 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
AU3894500A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Prevention of cardiovascular disease
AU3757200A (en) 1999-03-19 2000-10-09 Knoll Gmbh Treatment of pulmonary hypertension
CN1161114C (zh) * 1999-03-19 2004-08-11 艾博特股份有限两合公司 一种治疗睡眠障碍的化合物在制药中的用途
AU4014800A (en) * 1999-03-19 2000-10-09 Knoll Gmbh Treatment of gallstones
US6441046B1 (en) 1999-03-19 2002-08-27 Abbott Gmbh & Co. Kg Control of metabolism
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
WO2000056309A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Method of treating sexual dysfunction
KR100432825B1 (ko) * 1999-03-19 2004-05-24 애보트 게엠베하 운트 콤파니 카게 식이 장애 치료용 약제학적 조성물
AU3760600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
NZ514016A (en) * 1999-03-19 2001-09-28 Knoll Gmbh Treatment of osteoarthritis
JP2002539251A (ja) * 1999-03-19 2002-11-19 クノール・ゲー・エム・ベー・ハー 治療薬に伴う体重増加を調節する方法
CN1352553A (zh) * 1999-03-19 2002-06-05 克诺尔股份有限公司 怀孕后的减肥
AU3895300A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9926251D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Pharmaceutical formulation
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
AU2001282913A1 (en) * 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
FR2814678B1 (fr) † 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
WO2002083631A1 (en) * 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
NZ534757A (en) * 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
JP2008526836A (ja) 2005-01-06 2008-07-24 シージェー チェイルジェダン コーポレーション シブトラミンの無機酸塩
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
JPWO2007024004A1 (ja) 2005-08-24 2009-03-05 萬有製薬株式会社 フェニルピリドン誘導体
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
EP1938811A4 (en) * 2005-09-22 2008-12-17 Eisai R&D Man Co Ltd MEDICAL COMPOSITION FOR THE TREATMENT OF BULAMINE AND BULAMIC DEPRESSIONS
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
EP1953165B1 (en) 2005-11-10 2012-02-01 Msd K.K. Aza-substituted spiro derivative
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
EP2063890A1 (en) 2006-09-07 2009-06-03 Nycomed GmbH Combination treatment for diabetes mellitus
EP2066329B1 (en) 2006-09-15 2017-09-06 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cyclobutylmethylamines
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
CA2664358A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diarylketimine derivative
KR20090127904A (ko) * 2007-04-09 2009-12-14 싸이도우스 엘엘씨. 스타틴과 항비만제의 복합물
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013354A (es) 2007-06-04 2010-07-06 Univ Ben Gurion Compuestos de triarilo y composiciones que los contienen.
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
WO2009110510A1 (ja) 2008-03-06 2009-09-11 萬有製薬株式会社 アルキルアミノピリジン誘導体
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Ｍｓｄ株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
CN102264228A (zh) 2008-10-22 2011-11-30 默沙东公司 用于抗糖尿病药的新的环状苯并咪唑衍生物
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010065889A2 (en) * 2008-12-06 2010-06-10 Auspex Pharmaceutical Cyclobutanemethanamine inhibitors of monomine reuptake
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10111880B2 (en) 2013-11-05 2018-10-30 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
CN113302189A (zh) 2018-11-20 2021-08-24 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB2184122B (en) * 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment

Also Published As

Publication number Publication date
IL92406A (en) 1995-07-31
EP0397831B1 (en) 1993-09-15
NL300066I1 (nl) 2001-12-01
DE68909219D1 (de) 1993-10-21
EP0397831A1 (en) 1990-11-22
NL300066I2 (nl) 2002-06-03
CA2003524A1 (en) 1990-05-29
AU4620789A (en) 1990-06-26
JPH02503682A (ja) 1990-11-01
DK175587B1 (da) 2004-12-13
PH26677A (en) 1992-09-15
DK177690D0 (da) 1990-07-26
LU90866I2 (fr) 2002-02-18
KR0164435B1 (ko) 1999-01-15
DK177690A (da) 1990-09-13
HK1006002A1 (en) 1999-02-05
IE893690L (en) 1990-05-29
IE61928B1 (en) 1994-11-30
ZA899058B (en) 1990-08-29
US5436272A (en) 1995-07-25
AU633529B2 (en) 1993-02-04
CA2003524C (en) 1999-10-19
DE68909219T2 (de) 1994-01-13
JPH06102622B2 (ja) 1994-12-14
WO1990006110A1 (en) 1990-06-14
DE19975039I2 (de) 2000-03-30

Similar Documents

Publication Publication Date Title
KR900701261A (ko) 비만증 치료방법
DE3674570D1 (de) N,n-dimethyl-1-(1-(4-chlorophenyl)-cyclobutyl)-3-methylbutylamin-hydrochlorid, monohydrat und pharmazeutische zusammensetzungen, welche diese enthalten.
KR910004187A (ko) 세트랄린을 사용한 조기사정의 치료방법
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
HK1003978A1 (en) Composition for the treatment of schizophrenia
IL76119A (en) Device for initiating reperfusion treatment when heart attack symptoms are present
KR920019342A (ko) 골질환 치료제
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
IL112515A (en) Pharmaceutical composition containing N,N-dimethyl-1-¬1-(4-chlorophenyl)cyclobutyl¾-3-methylbutylamine for use in the treatment of non-insulin dependent diabetes mellitus
ES2001996A6 (es) Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad.
Christodoulou et al. Abrupt lithium discontinuation in manic‐depressive patients
CA2151724A1 (en) Antipyretic and Analgesic Methods and Compositions Containing Optically Pure R-Ketorolac
HU907011D0 (en) Process for producing preparatives containing sertralines
MX173567B (es) Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih
KR950701820A (ko) 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
KR930002322A (ko) 피라졸 유도체
CA2139353A1 (en) Pharmaceutical composition containing il-6, their uses for the treatment of consumptive thrombo-hemorrhagic disorder
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
KR890007728A (ko) 진통제 제조방법
FR2244481A1 (en) Oral treatment of diabetes - with a complex of glibenclamide and phenformin
KR910700263A (ko) 시클로리노펩티드를 포함하는 의약
MX9710093A (es) Uso de aminas alilicas.
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
KR950700063A (ko) 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)
KR880000094A (ko) 위염치료제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
J206 Request for trial to confirm the scope of a patent right
J301 Trial decision

Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20041122

Effective date: 20051031

Free format text: TRIAL NUMBER: 2004100002520; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20041122

Effective date: 20051031

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20051206

Effective date: 20061115

Free format text: TRIAL NUMBER: 2005200010459; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20051206

Effective date: 20061115

J206 Request for trial to confirm the scope of a patent right
J301 Trial decision

Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20070518

Effective date: 20071031

Free format text: TRIAL NUMBER: 2007100001314; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20070518

Effective date: 20071031

FPAY Annual fee payment

Payment date: 20120830

Year of fee payment: 15

EXPY Expiration of term